Clinical trials
EGFR clinical trials
Below are recruiting egfr clinical trials, each written for real people, not researchers. We’re tracking 232 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06830551Recruiting
Cord blood serum eye drops for severe eye problems from anti-EGFR treatment
This trial tests whether cord blood serum eye drops can help with severe dry eye or corneal damage caused by anti-EGFR cancer treatment. If you have advanced cancer with an EGFR mutation and are struggling with eye irritation or vision problems from your medication, this study might offer a new way to help.
BolognaAges 18 years+ - NCT06830694RecruitingPhase 2
Trial of a new drug combo for a rare type of lung cancer
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Seoul, Gangnam-guAges 19 years+ - NCT06838273RecruitingPhase 3
Testing a new drug combo for EGFR-mutated lung cancer
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06863506RecruitingPhase 2
Study of Befotertinib for non-small cell lung cancer with uncommon EGFR mutations
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Hangzhou, ZhejiangAges 18 years+ - NCT06873880Recruiting
Nutrition check for hemodialysis patients
This study looks at how well a simple body measurement combined with a blood test can help assess nutrition in people on hemodialysis. It aims to find a better way to check if you're getting enough nutrients.
Tartu, TartuAges 18 years+ - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT06962865RecruitingPhase 2
RC108 and Furmonertinib for first-line treatment of EGFR-mutated and MET-positive NSCLC
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
BeijingAges 18–75 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT07062952Recruiting
Salt substitute to protect kidney after tumor surgery
This study tests whether using a salt substitute instead of regular salt can help protect kidney function after kidney tumor surgery. It is for people who had a kidney removed (either full or partial) and whose remaining kidney is working well.
Nanjing, JiangsuAges 18 years+ - NCT07070440RecruitingPhase 1/Phase 2
New combination therapy for advanced EGFR-mutated lung cancer
This trial tests a new combination therapy (DZD6008 plus other drugs) for people with advanced lung cancer that has an EGFR mutation and has stopped responding to a third-generation targeted therapy. It aims to find a better treatment option for these patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07092202RecruitingPhase 4
Firmonertinib and spinal injection for EGFR lung cancer with spread to brain lining
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
Wuhan, HubeiAges 18 years+ - NCT07117890RecruitingPhase 2
Sunvozertinib for untreated NSCLC with EGFR rare mutations
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
ShanghaiAges 18 years+ - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+ - NCT07182682RecruitingPhase 3
Sunvozertinib after surgery for early-stage NSCLC with certain EGFR mutations
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
BeijingAges 18 years+ - NCT07183189RecruitingPhase 3
New drug combo vs standard for EGFR-mutated lung cancer
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT07217028RecruitingPhase 1
Safety study of a new PET tracer for head and neck cancer
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
Nashville, TennesseeAges 18 years+ - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07304739RecruitingPhase 2
Furmonertinib plus radiation and chemo for EGFR lung cancer with brain spread
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Cangzhou, HebeiAges 18–75 - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07343986RecruitingPhase 1
Ultrasound and Immunotherapy for Newly Diagnosed Brain Cancer
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
Charlottesville, VirginiaAges 18–70
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for egfr?
- Yes. Clin2 currently lists 232 recruiting egfr studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a egfr trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a egfr trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.